Lower‐dose intravenous immunoglobulins for the treatment of fetal and neonatal alloimmune thrombocytopenia: a cohort study

Abstract

In pregnancies with FNAIT with a previous affected child without ICH, treatment with IVIG in a weekly dose of 0.5 or 1.0 g/kg results in comparable neonatal PLT count at birth and degree of thrombocytopenia.

Low‐dose prednisone and immunoglobulin G treatment for woman at risk for neonatal alloimmune thrombocytopenia and T helper 1 immunity

“…Universal screening for FNAIT is not recommended during the routine antenatal screening although FNAIT is not uncommon 22. Prenatal screening for FNAIT in highrisk population revealed an actual risk for FNAIT, and the prevention of maternal sensitization by the serial monitoring and immunosuppression with low-dose prednisone and short-term intravenous immunoglobulin G infusion (during the third trimester of the second pregnancy) resulted in two successful pregnancies in this case.…”

“…30 Our results also showed that women with ITP had elevated TNFα/IL-10 and IFN-ϒ/IL-10 ratios. 16,22,29,31 However, only about 30% of the HPA-1anegative women with this HLA antigen are immunized. A 0 or Th2 pattern after IVIG gave the best prognosis, whereas sustained high expression of IFNγ and refractoriness to IVIG were the main indicators of poor prognosis.…”

“…Prenatal screening for FNAIT in highrisk population revealed an actual risk for FNAIT, and the prevention of maternal sensitization by the serial monitoring and immunosuppression with low-dose prednisone and short-term intravenous immunoglobulin G infusion (during the third trimester of the second pregnancy) resulted in two successful pregnancies in this case. In this case, when IgM antibodies were not down-regulated with prednisone treatment, IVIG treatment was initiated weekly 17,22. In this case, the patient had an older sister who had a history of FNAIT, which led the patient to seek for further evaluation.…”

Clinical indications for intravenous immunoglobulin utilization in a tertiary medical center: a 9‐year retrospective study

“…Evidence accumulated regarding ITP, Kawasaki disease, GBS, and CIDP has led to FDA authorization. Furthermore, small‐scale studies had shown that many IVIG may provide benefit in many other autoimmune diseases . Despite its beneficial effects, the specific mechanism of action of IVIG remains unclear and probably modulates the immune system via multiple pathways …”

“…Furthermore, small-scale studies had shown that many IVIG may provide benefit in many other autoimmune diseases. 20,[31][32][33][34][35] Despite its beneficial effects, the specific mechanism of action of IVIG remains unclear and probably modulates the immune system via multiple pathways. 35,36 In 2012, 75% of IVIG was delivered to patients with autoimmune or inflammatory diseases in the United States.…”